Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors

PURPOSE: Linifanib is a selective inhibitor of the vascular endothelial growth factor and platelet-derived growth factor family of tyrosine kinase inhibitors. The purpose of this high-precision QT study was to evaluate the effects of linifanib on cardiac repolarization in patients with advanced meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Yi-Lin, LoRusso, Patricia, Hosmane, Balakrishna, Ricker, Justin L., Awni, Walid, Carlson, Dawn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889813/
https://www.ncbi.nlm.nih.gov/pubmed/24241212
http://dx.doi.org/10.1007/s00280-013-2351-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889813/
https://www.ncbi.nlm.nih.gov/pubmed/24241212
http://dx.doi.org/10.1007/s00280-013-2351-2

Ejemplares similares